Lawsuits Prompt Manufacturer to Seek Antidote for Pradaxa Bleeding

The length of time necessary to create a working formula that will cure the internal bleeding caused by Pradaxa has not been determined, though projection states that months or years may pass before a working antidote is available. No matter how long it will take to create a working formula that will stop Pradaxa bleeding, those who were already injured, were killed, or whose conditions were worsened by Pradaxa will not benefit in any way from it.  

The reality exists that if Boehringer Ingelheim is working to develop an antidote to Pradaxa bleeding as reported, it can now be regarded as evidence in the Pradaxa lawsuits — specifically, that an attempt to make an antidote before applying for FDA approval should have been made. If the defendant uses the defense that they had no knowledge that antidotes or remedies that were effective in internal bleeds caused by alternate drugs like Pradaxa would be ineffective on Pradaxa itself, they may be making a trade of one problem for another. Given the fact that for decades antidotes for bleeds have existed, Pradaxa lawyers are likely to argue that Pradaxa manufacturers are responsible for tests to determine if this antidote that was so effective on alternate drugs would also be effective with Pradaxa.

It will be a tough battle for the defendant in trying to fend off the charges being made in the Pradaxa bleeding lawsuits. If they failed to test the common remedy to see how effective it was with bleeding caused by Pradaxa, they will have to come up with an effective defense for this. If they did test the common remedy and had knowledge that it failed to work for internal bleeds brought on by Pradaxa, they will have to account for the deception on their part in failing to notify the FDA and the general public that the antidote was ineffective if used for Pradaxa internal bleeds. No defense by the defendant seems to exist concerning this issue.